股票表现 - UiPath (PATH) 最新收盘价为 $23.60，较前一日上涨了 +1.77% [1] - UiPath 的股票表现优于标普500指数，标普500指数当日上涨了 1.03% [1] - UiPath 的股票在过去一个月中下跌了 1.24%，落后于商业服务行业的增长率 6.35% 和标普500指数的增长率 3.21% [2] 财务预测 - UiPath 将于 2024 年 3 月 13 日公布财报，预计每股收益为 $0.15，营收预计为 $383.32 亿美元，同比增长 24.23% [3] - UiPath 目前的前瞻市盈率为 47.05，高于行业平均值 27.24 [7] - UiPath 目前的 PEG 比率为 1.34，与行业平均值 1.53 相比 [8] 分析师评级 - 投资者应密切关注 UiPath 的分析师预测变化，这些变化通常反映了短期业务模式的变化 [4] - Zacks Rank 模型显示，UiPath 目前的评级为 3 (Hold)，过去 30 天内一致的每股收益预测保持不变 [6] 行业评级 - 技术服务行业隶属于商业服务行业，目前该行业的 Zacks Industry Rank 为 82，在 250 多个行业中排名前 33% [9] - Zacks Industry Rank 评估了不同行业群体的实力，研究显示排名前 50% 的行业胜过后 50% 的行业 [10]

UiPath, Inc. (PATH) is scheduled to report its fourth-quarter fiscal 2024 results on Mar 13, after the bell.The company has an impressive earnings surprise history. Earnings surpassed the Zacks Consensus Estimate in the last four quarters, delivering a surprise of 208.9% on average.UiPath, Inc. Price and EPS Surprise  Q4 ExpectationsThe Zacks Consensus Estimate for PATH’s revenues in the to-be-reported quarter is pegged at $383.3 million, indicating a 24.2% year-over-year increase. We expect the company’s s ...

UiPath Inc. NYSE: PATH is the leader in artificial intelligence (AI) powered robotic process automation (RPA) and business process automation (BPA) platforms in the computer and technology sector. A recent MarketBeat Original article by Chris Markoch explores how ARK Investment Management head Cathie Wood is a believer in UiPath since it’s the second largest holding in her Ark Innovation ETF NYSEARCA: ARKK.UiPath benefits from two secular tailwinds: AI and automation. The company is scheduled to report its ...

NEW YORK & RIYADH, Saudi Arabia--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced that the Ministry of Tourism of the Kingdom of Saudi Arabia is using AI-powered automation in its mission to establish the Kingdom as a thriving global destination and make tourism a leading industry of its dynamic and diverse economy. The Ministry is leveraging the UiPath Business Automation Platform to further its national tourism strategy, which rests on increasi ...

UiPath在沙特阿拉伯推出AI和自动化解决方案 - UiPath在沙特阿拉伯推出了AI和自动化解决方案，包括文件理解、Clipboard AI和UiPath Autopilot™[3] - UiPath的AI和自动化解决方案可以帮助沙特阿拉伯的政府机构和消费型企业实现数字转型，提升员工和客户体验[4] UiPath在沙特阿拉伯开设首个办公室 - UiPath宣布在沙特阿拉伯开设首个办公室，并承诺90%的员工将是沙特阿拉伯国籍[5] UiPath与沙特数字学院合作推出沙特自动化学校 - UiPath与沙特数字学院合作，推出首个沙特自动化学校，旨在加速沙特未来劳动力的发展[6] UiPath首席执行官将在LEAP 2024发表主题演讲 - UiPath首席执行官将在LEAP 2024发表主题演讲，探讨人工智能如何推动人类成就[7] UiPath的业务自动化平台在沙特阿拉伯可用 - UiPath的业务自动化平台在沙特阿拉伯可用，包括云端和本地解决方案[8]

UiPath股价表现 - UiPath (PATH)最新收盘价为$23.75，较前一交易日上涨了+1.67%[1] - UiPath股票的变动超过了标普500指数的日涨幅0.52%[1] - UiPath企业自动化软件开发商的股价在过去一个月中上涨了1.65%[2] UiPath财务数据 - UiPath将于2024年3月13日发布财报，预计每股收益为$0.15，营收预计为$383.32百万美元[3] - UiPath目前的Zacks Rank为3 (Hold)，Forward P/E比率为47.4，PEG比率为1.35[6][7][8] 技术服务行业评级 - Technology Services行业的Zacks Industry Rank为91，属于所有行业的前37%[9] - Zacks Industry Rank评估了特定行业群体的活力，显示排名前50%的行业胜过后50%的行业[10]

UiPath盈利预期 - UiPath当前季度预计每股盈利为0.15美元，与去年同期持平[5] - UiPath当前财年的盈利预期为0.47美元，较去年增长235.7%[6] - UiPath下一财年的盈利预期为0.49美元，较去年增长5.8%[7] UiPath股价表现 - UiPath是一家企业自动化软件开发商，近期股价表现相对较差[1] - UiPath的Zacks Rank评级为3（持有），显示股价走势可能与整体市场表现一致[8] UiPath财务数据 - UiPath上一季度营收为3.2592亿美元，同比增长24.1%，每股收益为0.12美元，同比增长71.43%[11] - UiPath在过去四个季度均超过了盈利预期，同时每次也超过了营收预期[13] UiPath估值评级 - UiPath的估值显示公司股价相对同行公司较高，Zacks Value Style Score评级为D[17]

股价表现 - UiPath (PATH) 最近的股价为$23.33，较前一天下跌了0.38% [1] - UiPath的股价在过去一个月上涨了2.58%，但落后于商业服务行业的6.34%和标普500指数的5.01% [2] 财务预测 - UiPath将于2024年3月13日发布财报，预计每股收益为$0.15，营收预计为$383.32百万美元，同比增长24.23% [3] 分析师观点 - 分析师对UiPath的预期调整可能会影响公司的业务前景 [4] 评级和估值 - Zacks Rank模型考虑了估值变化，UiPath目前的Zacks Rank为3 (Hold) [5] - UiPath的前瞻市盈率为47.52，高于行业平均值24.96 [6] - PATH目前的PEG比率为1.36，略低于行业平均值1.55 [7] 行业排名 - 技术服务行业属于商业服务行业，目前Zacks Industry Rank为85，位于超过250个行业的前34% [8] - Zacks Industry Rank显示，评级较高的行业通常表现优于评级较低的行业 [9]

Vertex Pharmaceuticals - Vertex Pharmaceuticals 在2023财年实现了强劲的收入增长，新的管道机会预示着未来的增长[3] - Vertex Pharmaceuticals 以其创新的囊性纤维化疗法而闻名，最近的批准项目包括与 CRISPR Therapeutics 合作的 Exa-Cel 和 VX-548，这些项目有望为公司的收入流提供多样化[4] - 预计 VX-548 和 Vanzacaftor Triple for CF 的 FDA 申请将是 2024 财年的两大增长催化剂，市场低估了 VX-548 的收入潜力，这可能为公司增加数十亿美元的市值[5]

BENGALURU, India--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise automation software company, today announced at the UiPath DevCon 2024 event a host of new features in its platform designed to enable developers to build, test, and accelerate implementation of automations. UiPath DevCon gathers hundreds of AI and automation developers, architects, engineers, testers, and product managers for a deep dive into innovation and collaboration possibilities for automation creators within the UiPath B ...